HPV阳性口咽癌降级治疗的研究进展

摘要/Abstract

摘要：

既往研究表明,人乳头状瘤病毒（HPV）阳性口咽癌患者的预后显著优于HPV阴性患者。但在标准治疗模式下,口咽癌患者严重不良反应发生率高,影响了治疗的可持续性。目前,国内外研究表明降级治疗是HPV相关性口咽癌未来治疗的趋势,该类患者的降级治疗模式也是目前研究的热点。降低化疗强度、降低放疗强度、通过联合治疗模式降低放化疗剂量等为HPV相关性口咽癌的降级治疗提供了进一步研究的方向。

关键词:口咽肿瘤,人乳头瘤病毒,降级治疗,适用人群

Abstract:

Previous studies have shown that patients with human papilloma virus（HPV）-positive oropharyngeal cancer have a significantly better prognosis than patients with HPV-negative oropharyngeal cancer. However, the high incidence of severe adverse reactions in patients with oropharyngeal cancer under the standard treatment mode affects the sustainability of treatment. At present, internal and overseas studies have indicated that step-down therapy is the trend of future treatment for HPV-associated oropharyngeal cancer, and the step-down therapy mode of these patients is also a hotspot of current research. Reducing the intensity of chemotherapy, reducing the intensity of radiotherapy, and reducing the dose of radiotherapy and chemotherapy through the combination therapy mode provide further research directions for the step-down therapy of HPV-associated oropharyngeal cancer.

Key words:Oropharyngeal neoplasms,Human papilloma virus,Step-down therapy,Indicated population

王琪, 王澜, 韩春. HPV阳性口咽癌降级治疗的研究进展[J]. 国际肿瘤学杂志, 2022, 49(4): 229-232.

Wang Qi, Wang Lan, Han Chun. Research progress on downgrading therapy for HPV positive oropharyngeal carcinoma[J]. Journal of International Oncology, 2022, 49(4): 229-232.

参考文献24

[1]	Lei L, Zheng RS, Peng K, et al. Incidence and mortality of oral and oropharyngeal cancer in China, 2015[J]. Chin J Cancer Res, 2020, 32(1): 1-9. DOI: 10.21147/j.issn.1000-9604.2020.01.01. doi:10.21147/j.issn.1000-9604.2020.01.01
[2]	Thompson-Harvey A, Yetukuri M, Hansen AR, et al. Rising incidence of late-stage head and neck cancer in the United States[J]. Cancer, 2020, 126(5): 1090-1101. DOI: 10.1002/cncr.32583. doi:10.1002/cncr.32583pmid:31722124
[3]	Ducatman BS. The role of human papillomavirus in oropharyngeal squamous cell carcinoma[J]. Arch Pathol Lab Med, 2018, 142(6): 715-718. DOI: 10.5858/arpa.2018-0083-RA. doi:10.5858/arpa.2018-0083-RApmid:29848036
[4]	Hong A, Lee CS, Jones D, et al. Rising prevalence of human papillomavirus-related oropharyngeal cancer in Australia over the last 2 decades[J]. Head Neck, 2016, 38(5): 743-750. DOI: 10.1002/hed.23942. doi:10.1002/hed.23942
[5]	Mehanna H, Franklin N, Compton N, et al. Geographic variation in human papillomavirus-related oropharyngeal cancer: data from 4 multinational randomized trials[J]. Head Neck, 2016, 38(Suppl 1): E1863-E1869. DOI: 10.1002/hed.24336. doi:10.1002/hed.24336
[6]	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)头颈部肿瘤诊疗指南: 2020[M]. 北京: 人民卫生出版社, 2020: 24-29.
[7]	Lassen P, Lacas B, Pignon JP, et al. Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: the MARCH-HPV project[J]. Radiother Oncol, 2018, 126(1): 107-115. DOI: 10.1016/j.radonc.2017.10.018. doi:10.1016/j.radonc.2017.10.018
[8]	Dogan S, Xu B, Middha S, et al. Identification of prognostic molecular biomarkers in 157 HPV-positive and HPV-negative squamous cell carcinomas of the oropharynx[J]. Int J Cancer, 2019, 145(11): 3152-3162. DOI: 10.1002/ijc.32412. doi:10.1002/ijc.32412
[9]	Lacas B, Carmel A, Landais C, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group[J]. Radiother Oncol, 2021, 156: 281-293. DOI: 10.1016/j.radonc.2021.01.013. doi:10.1016/j.radonc.2021.01.013
[10]	Rosenthal DI, Harari PM, Giralt J, et al. Association of human papillomavirus and p16 status with outcomes in the IMCL-9815 phase Ⅲ registration trial for patients with locoregionally advanced oropharyngeal squamous cell carcinoma of the head and neck treated with radiotherapy with or without cetuximab[J]. J Clin Oncol, 2016, 34(12): 1300-1308. DOI: 10.1200/JCO.2015.62.5970. doi:10.1200/JCO.2015.62.5970pmid:26712222
[11]	Bonner JA, Giralt J, Harari PM, et al. Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: assessment from a phase 3 registration trial[J]. Eur J Cancer, 2016, 64: 1-11. DOI: 10.1016/j.ejca.2016.05.008. doi:10.1016/j.ejca.2016.05.008pmid:27323346
[12]	Gillison ML, Trotti AM, Harris J, et al. Radiotherapy plus cetu-ximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial[J]. Lancet, 2019, 393(10166): 40-50. DOI: 10.1016/S0140-6736(18)32779-X. doi:S0140-6736(18)32779-Xpmid:30449625
[13]	Mehanna H, Robinson M, Hartley A, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial[J]. Lancet, 2019, 393(10166): 51-60. DOI: 10.1016/S0140-6736(18)32752-1. doi:S0140-6736(18)32752-1pmid:30449623
[14]	Suton P, Skelin M, Rakusic Z, et al. Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE[J]. Eur Arch Otorhinolaryngol, 2019, 276(5): 1275-1281. DOI: 10.1007/s00405-019-05387-8. doi:10.1007/s00405-019-05387-8
[15]	Chera BS, Amdur RJ, Tepper JE, et al. Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma[J]. Cancer, 2018, 124(11): 2347-2354. DOI: 10.1002/cncr.31338. doi:10.1002/cncr.31338
[16]	Lim SH, Lee SJ, Ahn MJ, et al. Different clinical outcomes between locally advanced hypopharyngeal and oropharyngeal cancer treated with definitive concurrent chemoradiotherapy: implication for subgroup selection for induction chemotherapy[J]. Jpn J Clin Oncol, 2016, 46(1): 40-45. DOI: 10.1093/jjco/hyv163. doi:10.1093/jjco/hyv163
[17]	Pearlstein KA, Wang K, Amdur RJ, et al. Quality of life for patients with favorable-risk HPV-associated oropharyngeal cancer after de-intensified chemoradiotherapy[J]. Int J Radiat Oncol Biol Phys, 2019, 103(3): 646-653. DOI: 10.1016/j.ijrobp.2018.10.033. doi:10.1016/j.ijrobp.2018.10.033
[18]	Ma DJ, Price KA, Moore EJ, et al. PhaseⅡevaluation of aggressive dose de-escalation for adjuvant chemoradiotherapy in human papillomavirus-associated oropharynx squamous cell carcinoma[J]. J Clin Oncol, 2019, 37(22): 1909-1918. DOI: 10.1200/JCO.19.00463. doi:10.1200/JCO.19.00463
[19]	Burr AR, Harari PM, Ko HC, et al. Reducing radiotherapy target volume expansion for patients with HPV-associated oropharyngeal cancer[J]. Oral Oncol, 2019, 92: 52-56. DOI: 10.1016/j.oralon-cology.2019.03.013. doi:10.1016/j.oralon-cology.2019.03.013
[20]	Seiwert TY, Foster CC, Blair EA, et al. OPTIMA: a phase Ⅱ dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer[J]. Ann Oncol, 2019, 30(2): 297-302. DOI: 10.1093/annonc/mdy522. doi:S0923-7534(19)31029-4pmid:31987428
[21]	Strohl MP, Wai KC, Ha PK. De-intensification strategies in HPV-related oropharyngeal squamous cell carcinoma-a narrative review[J]. Ann Transl Med, 2020, 8(23): 1601. DOI: 10.21037/atm-20-2984. doi:10.21037/atm-20-2984
[22]	Misiukiewicz K, Gupta V, Miles BA, et al. Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV⁺oropharyngeal carcinoma patients: the Quarterback trial[J]. Oral Oncol, 2019, 95: 170-177. DOI: 10.1016/j.oraloncology.2019.06.021. doi:S1368-8375(19)30210-6pmid:31345387
[23]	Hegde JV, Shaverdian N, Daly ME, et al. Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: findings from a phase 2 trial[J]. Cancer, 2018, 124(3): 521-529. DOI: 10.1002/cncr.30954. doi:10.1002/cncr.30954pmid:29044458
[24]	Marur S, Li S, Cmelak AJ, et al. E1308: phase Ⅱ trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx-ECOG -ACRIN Cancer Research Group[J]. J Clin Oncol, 2017, 35(5): 490-497. DOI: 10.1200/JCO.2016.68.3300. doi:10.1200/JCO.2016.68.3300